In the current study, we sought to identify bone marrow-derived mononuclear cell (BM-MNC) subpopulations associated with a combined improvement in left ventricular ejection fraction (LVEF), left ventricular endsystolic volume (LVESV), and maximal oxygen consumption (VO 2 max) in patients with chronic ischemic cardiomyopathy 6 months after receiving transendocardial injections of autologous BM-MNCs or placebo. For this prospectively planned analysis, we conducted an embedded cohort study comprising 78 patients from the FOCUS-Cardiovascular Cell Therapy Research Network (CCTRN) trial. Baseline BM-MNC immunophenotypes and progenitor cell activity were determined by flow cytometry and colony-forming assays, respectively. Previously stable patients who demonstrated improvement in LVEF, LVESV, and VO 2 max during the 6-month course of the FOCUS-CCTRN study (group 1, n = 17) were compared to those who showed no change or worsened in one to three of these endpoints (group 2, n = 61) and to a subset of patients from group 2 who declined in all three functional endpoints (group 2A, n = 11). Group 1 had higher frequencies of B-cell and CXCR4 + BM-MNC subpopulations at study baseline than group 2 or 2A. Furthermore, patients in group 1 had fewer endothelial colony-forming cells and monocytes/macrophages in their bone marrow than those in group 2A. To our knowledge, this is the first study to show that in patients with ischemic cardiomyopathy, certain bone marrow-derived cell subsets are associated with improvement in LVEF, LVESV, and VO 2 max at 6 months. These results suggest that the presence of both progenitor and immune cell populations in the bone marrow may influence the natural history of chronic ischemic cardiomyopathy-even in stable patients. Thus, it may be important to consider the bone marrow composition and associated regenerative capacity of patients when assigning them to treatment groups and evaluating the results of cell therapy trials.
INTRODUCTION
Clinical investigations of heterogeneous bone marrowderived mononuclear cells (BM-MNCs) to treat patients with acute myocardial infarction (MI) or chronic ischemic heart failure (HF) have not met early expectations for success 1-3 . These variable findings have highlighted the need for studies aimed at improving our understanding of whether the mechanisms and pathways associated with endogenous cardiac repair involve BM-MNCs. In our recently reported study of an acute MI cohort, we found that improved patient outcomes were associated with higher frequencies of CD31 + BM-MNCs and with higher growth rates in colony-forming assays 4 , suggesting that both cell number and function can contribute to patient outcomes. However, in that study, we examined associations between bone marrow (BM) cell populations and patient outcomes only in the cell-treated group and only shortly after acute MI. It is unknown whether there are specific cell populations in the BM that affect cardiac repair independently of treatment, especially in patients with HF. In the current study, we sought to identify BM-MNC subpopulations associated with a rigorous definition of improved cardiac function in patients with HF. The FOCUS-Cardiovascular Cell Therapy Research Network (FOCUS-CCTRN) clinical trial, which assessed the effects of BM-MNC therapy in patients with chronic ischemic HF, showed negative results for all three primary endpoints [left ventricular end-systolic volume (LVESV), maximal oxygen consumption (VO 2 max), and reversibility on single-photon emission tomography (SPECT)], but a 2.7% difference in the exploratory endpoint left ventricular ejection fraction (LVEF) between the cell-and placebo-treated patients at 6 months 1,5,6 . We regrouped FOCUS-CCTRN patients according to outcome using a combined criterion of improved LVEF, LVESV, and VO 2 max with the goal of identifying associations between the BM-MNC profile and functional outcomes. Although a reversible defect by SPECT was originally one of the three primary endpoints chosen for the FOCUS study, it became obvious during the study that signal noise exceeded the expected bounds; accordingly, SPECT measurements were not included in our multiple parameter determination of functional improvement for this analysis.
It is rare to see HF patients in whom LVEF, LVESV, and VO 2 max improve at the same time; thus, by requiring favorable changes in all three of these cardiac functional parameters, we set a rigorous criterion for identifying patients who improved in the FOCUS-CCTRN trial. We reasoned that applying this criterion and comparing the BM profile of patients who improved to the BM profile of patients who did not could contribute to a better understanding of BM factors associated with positive functional changes. Accordingly, we identified the subgroup of participants in the FOCUS-CCTRN trial who showed improvement in LVEF, LVESV, and VO 2 max at the 6-month follow-up and then performed a cohort analysis to determine whether the composition of their BM-MNC samples at study onset differed from that of patients who did not improve in all three functional outcomes over the same period.
MATERIALS AND METHODS

Participants and Procedures
The FOCUS-CCTRN trial 1 was conducted at five clinical sites, and institutional review board approval was obtained from each site. The study complied with the Declaration of Helsinki, and informed consent was obtained for all patients. Of the 92 patients who were randomized and eligible for participation in this analysis, 78 had complete follow-up data and consented to have a portion of their BM-MNC product analyzed.
BM Collection and Analysis
BM samples were obtained and processed according to previously published methods 1 . Briefly, the BM-MNC concentration was adjusted to produce a fixed dose of autologous cells, as described by Gee et al. 7 . The target dose of BM-MNCs was 100 × 10 6 . The treatment (BM-MNCs or placebo) was administered to the patient in 15 separate injections (0.2 ml each) to left ventricular (LV) endocardial regions identified as viable by electromechanical mapping on the day of BM collection within 12 h of aspiration 1 . The excess fresh BM-MNC product was shipped to the Biorepository Core, where the functional activity (via colony-forming assays) and immunophenotype (via flow cytometry) were determined, as described previously 8 .
To characterize the hematopoietic stem cells, endothelial progenitor cells (EPCs), and immune cells in the BM, 1-5 × 10 6 viable cells were labeled with anti-CD45-PerCP-Cy5.5, anti-CD34-PE-Cy7, anti-CD133-PE (Miltenyi Biotec, Auburn, CA, USA), anti-CD306 vascular endothelial growth factor receptor (VEGFR2/ KDR)-APC (R&D Systems, Minneapolis, MN, USA), anti-CD31-FITC, anti-CD3-PE-Cy7, anti-CD19-APC-H7, anti-CD11b-APC, anti-CXCR4-PE, and anti-CD14-FITC or an isotype-matched control antibody. Cell surface markers were analyzed using FlowJo software 7.6.5 (Tree Star, Ashland, OR, USA). Data analysis was performed by gating the individual lymphocyte, monocyte, and gran ulocyte populations on the basis of their forward scatter (FSC-A) versus side scatter (SSC-A) properties. The frequencies of single-, double-, and triple-labeled cell populations (Table 1 ) and subsets were determined as a function of CD45 expression. Unless otherwise indicated, single-marker expression included CD45 + and CD45 − cells. Expression of CD14 and CD11b and secondary markers were assessed in the monocyte fraction, whereas the expression of CD19, CD3, CD31, CD34, KDR, and CXCR4 and secondary markers were assessed in the lymphocyte fraction. A modified version 9 of the International Society of Hematotherapy and Graft Engineering (ISHAGE) sequential gating strategy 10 was used to analyze the CD34 + , CD133 + , and KDR + EPCs in the total nucleated cell fraction.
The gating strategies for the cell populations found to be significant are shown in Figures 1 and 2 . In addition to cell populations expressing a given marker, certain subsets within those populations were also gated [e.g., negative (neg) , dim (dim) , intermediate (intermed) , or bright (bright) ] as indicated (Fig. 2D ). The negative gate was always placed on the basis of the isotype control negative signal.
Endothelial cell function was quantified by using the endothelial colony-forming cell (ECFC) assay (reported as ECFC per 10 8 cells) and the CFU-Hill assay (reported as CFU-EC) by using commercial kits according to the manufacturers' instructions (STEMCELL Technologies, Vancouver, Canada), as previously described 8 .
Embedded Cohort Analysis
The purpose of this analysis was to determine whether patients with a favorable cardiac functional outcome at 6 months had specific BM characteristics at study baseline that differed from those who did not improve. This evaluation of the putative relationships between BM-MNC immunophenotypes and LV function was prespecified in the FOCUS-CCTRN protocol. In the FOCUS-CCTRN trial, patients were randomized 2:1 to cell treatment or placebo. In the cell-treated patients, no significant beneficial effects of therapy were observed for LVESV or VO 2 max, whereas a small improve ment in LVEF (2.7%, p = 0.03) occurred. We combined the BM-MNC and placebo groups into a single cohort characterized by chronic ischemic cardiomyopathy and HF, which increased the statistical power for the current analyses. A cohort approach was used to compare the baseline BM-MNC profiles of patients who improved in three available cardiac function indicators (LVEF, LVESV, and VO 2 max) to those of patients who did not improve. Left ventricular end-diastolic volume (LVEDV) was not an endpoint of this study and was not considered.
Patients in the placebo and cell-treated groups were reassigned to three different groups based on their 6-month functional outcomes: (1) group 1 (n = 17): patients who showed improvement in all three endpoints (i.e., an increase in LVEF, a decrease in LVESV, and an increase in VO 2 max), (2) group 2 (n = 61): all other patients, and (3) group 2A (n = 11): a subset of group 2 that included only individuals who showed a decline in all three endpoints. We then determined whether the baseline BM-MNC immunophenotypes and functions of the three groups differed at 
It is important to note that we grouped patients based on functional endpoints rather than treatment; therefore, the composition of the three groups differed in regard to treatment received. Group 1 (triple-positive functional outcomes) included 16 BM-MNC-treated and 1 placebo-treated patients, group 2 (all others) included 35 BM-MNC-treated and 26 placebo-treated patients, and group 2A (triple-negative functional outcomes) included 7 BM-MNC-treated and 4 placebo-treated patients.
Statistical Methods
Measures of central tendency and dispersion were compared. Patient demographic and clinical data were compared by using the Student's t-test for continuous variables and were reported by mean and standard error of the mean (SEM). Wilcoxon two-sample testing was used for the nonparametric evaluations [brain natriuretic peptide BNP(reg) and BNP(pro)]. Fisher's exact test was used to compare dichotomous variables. Differences in the New York Heart Association classification and the Canadian Cardiovascular Society classification were assessed by using the chi-square test. Differences in phenotype and function data were assessed by using the Student's t-test. Statistical comparisons with a value of p < 0.05 were considered significant with no corrections for multiplicity in this wide-ranging evaluation.
Heat Map
To visualize the distribution of cell phenotypes and changes present in group 1 versus groups 2 and 2A, we generated a heat map showing the relative change in frequencies of a given cell population or function. The signal-to-noise ratio (SNR), calculated as the delta percent difference in group 1 versus groups 2 and 2A divided by the standard error, was plotted for each cell population and function. Green represents a positive SNR (i.e., an absolute higher cell percentage or function), black represents no difference, and red represents a negative SNR (i.e., an absolute lower cell percentage or function).
RESULTS
Comparisons Between Group 1 and Group 2 Patients
By definition, at the 6-month follow-up, group 1 showed greater improvement in LVEF, LVESV, and VO 2 max, as compared to group 2 (Table 2) . Other baseline demographic and clinical data for groups 1 and 2 are shown in Table 3 . Patients in group 1 had significantly lower BNP levels and a significantly smaller percentage who underwent coronary Data presented as mean (SD). Cell phenotype data shown as the cell frequency in the lymphocyte fraction of the bone marrow (BM), except for the CD45 + CD11b + population, which is shown as the cell frequency in the monocyte fraction of the BM. *Group 2: n = 60. †Group 2: n = 58. artery bypass graft (CABG) surgery than in group 2. The age in groups 1 and 2 did not statistically differ, but there was a trend (p = 0.067) toward a lower age in group 1. Flow cytometry showed that the frequencies of eight cell populations were significantly elevated in the BM of patients in group 1 when adjusted for age, as compared to the frequencies in group 2 patients (Table 4 ). The elevated populations included CD11b + , CD31 dim , CD19 + , and CXCR4 + cells and subsets thereof. In terms of absolute percentages, these cell populations were increased by 1-7% (Fig. 3A) . It was not possible to adjust the results for baseline BNP since BNP was not measured in the same manner across sites. When the data were adjusted for CABG, the CXCR4 + and CXCR4 intermed cell populations were no longer significantly different between groups 1 and 2.
Comparisons Between Group 1 and Group 2A Patients
As a more constrained approach, we compared the patients with the best functional outcomes (triple-positive patients, group 1) to those with the worst outcomes (triplenegative patients, group 2A). Group 1 and group 2A membership was defined on the basis of changes in LVEF, VO 2 max, and LVESV and, therefore, had the expected differences in these variables ( Table 2 ). The differences in LVEF, VO 2 max, and LVESV were greater when group 1 was compared with group 2A than when it was compared with group 2. A comparison of other baseline demographic and clinical variables showed that the patients in group 1 were significantly younger than those in group 2A and had significantly lower BNP levels (Table 3 ). Four hematopoietic/ immune cell populations (CD45 + CD19 + , CD19 + CD11b + , CD19 + CXCR4 + , and CD45 + CD11b + cells) were significantly higher in the BM of group 1 than in group 2A (Table 5 and Fig. 3B ), whereas both the percentage of CD45 + CD31 bright cells and the number of ECFCs per 10 8 cells were lower (Table 5 and Fig. 3C ). This remained true after adjustment for age.
BM-MNC Characteristics Associated With Positive Functional Outcomes
The heat map shown in Figure 4 was designed to enable high-level comparisons between group 1 and groups 2 and 2A. These comparisons are shown for a total of 33 variables: 31 BM-MNC frequencies and 2 cell functions (CFU-EC and ECFC). A positive SNR was observed for 48% of these variables in the group 1 versus group 2 comparison and for 69% in the group 1 versus group 2A comparison. In the comparison of group 1 versus group 2, the primary cell populations with a positive SNR were hematopoietic and immune cells. However, approximately twice as many progenitor cell populations (12 vs. 7) showed a positive SNR in the comparison of group 1 versus group 2A. This difference suggests that higher endogenous levels of progenitor cells may predict a beneficial cardiac outcome.
DISCUSSION
The current study was designed to determine whether improvements in three important functional endpoints (LVEF, LVESV, and VO 2 max) in patients with ischemic cardiomyopathy were associated with the frequency of certain cell types in the patient's BM. The effect of treatment was outside the scope of this study, but of the 17 patients in group 1 (i.e., those who showed improvement for all three endpoints), 16 were treated with BM-MNCs. We found that HF patients who improved in a combination of LVEF, LVESV, and VO 2 max at the 6-month follow-up had higher levels of CD19 + B cells, CD11b + monocytes, CD31 dim subsets, and CXCR4 + migratory cells and lower levels of CD31 bright lymphocyte subsets in their BM at baseline than patients who improved in fewer endpoints or whose condition worsened.
Our results suggest that B cells may either play a beneficial role in repair, or their numbers may serve as predictors of a favorable functional outcome in chronic ischemic cardiomyopathy patients. The increased frequencies of B-cell subsets (CD19 + CXCR4 + and CD19 + CD11b + ) in the BM may be due to either an increase in B-cell production (for potential cardiac repair) or a decrease in B-cell mobilization from the BM. The latter possibility seems less likely, given the increase in markers associated with migratory capability (CD11b and CXCR4) in the B-cell subsets.
Cell subsets expressing CXCR4, including CD19 + B cells, were also elevated in the BM-MNCs of patients who had superior functional outcomes. Several studies have identified CXCR4 and its ligand, stromal cellderived factor-1 (SDF-1), as key molecular contributors to myocardial repair 11, 12 . Although the present study was Data presented as mean (SD). Cell phenotype data shown as the cell frequency in the lymphocyte fraction of the BM, except for the CD45 + CD11b + population, which is shown as the cell frequency in the monocyte fraction of the BM. ECFC, endothelial colony-forming cells. *Group 1: n = 16, group 2A: n = 9. not designed to, and therefore did not directly, assess cell recruitment or the incorporation of cells at cardiac injury sites, the association we found between higher numbers of CXCR4-expressing cells and functional improvement suggests that better cell migratory capacity in response to tissue injury or ischemia could contribute to improved outcome. Several reports have suggested that monocytes and macrophages play a critical role both in cardiac repair and in angiogenesis and arteriogenesis [13] [14] [15] . In this study, we found that the BM frequency of CD45 + CD11b + monocytes was higher in group 1 than in groups 2 and 2A. Other studies have shown contradictory results about the role of CD11b on cardiac function. For instance, Frantz et al. 16 demonstrated increased mortality in macrophageand CD11b + Ly6G + monocyte-depleted mice after MI compared with controls. However, Cogle et al. 13 reported that increased levels of BM CD11b + cells are associated with reductions in LVEF after acute MI, and Maier et al. 15 showed that continuous CD11b + cell infiltration is associated with chronic inflammation, fibrosis, and myocyte atrophy. Although the reason for these conflicting results is unclear, differences in disease severity, the fact that CD11b is expressed on a diverse array of immune cell populations (e.g., monocytes, granulocytes, natural killer, and B cells) 17-19 , and the recently described heterogeneity within monocyte/macrophage populations 14,20 may be contributing factors.
Associations between cardiovascular disease outcomes and the frequency of CD31 + cells have been reported previously 4,21 . The frequency of CD31 dim lymphocytes has been shown to be inversely correlated with cardiovascular risk factors, such as age, male sex, and CRP level, whereas CD31 bright monocytes have been found to be positively associated with cardiovascular risk factors 22 . We observed that the frequency of CD31 dim cells in the BM was significantly higher in group 1 than in group 2. In contrast, the frequency of CD45 + CD31 bright cells in the BM was significantly lower in group 1 than in group 2A. It is currently unknown whether these BM CD31 bright and CD31 dim cells are positively associated with cardiovascular risk factors. However, the BM frequency and function of CD31 dim and CD31 bright BM subsets, as well as their relationship to cardiovascular risk factors, may warrant future study in candidates for stem cell therapy.
An unexpected finding in this study was the lower levels of BM ECFCs in group 1, as compared to the levels in group 2A. Peripheral blood ECFC levels have been reported to be low (0-3 ECFCs per 10 8 mononuclear cells) in healthy individuals 23,24 but to increase approximately 10-fold in patients with acute MI at 3 h after symptom onset, indicating increased mobilization Heat map illustrating signal-to-noise ratios of bone marrow cell variables for group 1 versus groups 2 and 2A. Relative differences are shown for BM-MNC subpopulation frequencies and functions of group 1 versus group 2 (left) and group 1 versus group 2A (right). Green = higher relative levels in group 1, black = no difference in relative levels, and red = lower relative levels.
of ECFCs to the circulation and ischemic tissue [25] [26] [27] . Our finding of lower ECFC levels in the BM of chronic HF patients is consistent with these previous studies in acute MI patients and may indicate greater mobilization of these cells to the ischemic myocardium.
A heat map analysis, which focused on cell population profiles, showed a high number of progenitor cell populations with a positive SNR in the group 1 versus group 2A comparison. This association, which occurred regardless of treatment type, supports the concept that the functional outcome is influenced by the patient's underlying progenitor cell profile/activity.
It is unknown why patients who were previously stable showed an improvement or decline in LV function. It is interesting to note that 16 of the 17 patients in group 1 received BM-MNCs. Furthermore, the difference in LVEF between group 1 and group 2A was greater than 10%, which is larger than the LVEF changes seen with many approved therapies in these patients. In addition, the fact that patients who showed improvement in LVEF, LVESV, and VO 2 max had a different BM profile than those who did not suggests that the underlying physiology of BM and its activation should not be ignored.
It has long been recognized that patient responses to treatments may differ substantially in a variety of clinical settings. Personalized medicine is based on the concept that optimal medical treatments may be tailored to the individual patient. In oncology, personalized therapy is already being used to select the most effective treatment option, including cell therapies, on the basis of the characteristics of the individual patient 28 . A similarly personalized approach may be possible for cardiovascular cell therapy, if the specific variables influencing outcomes can be identified. The current findings suggest that both progenitor and nonprogenitor (e.g., hematopoietic and immune) cells are associated with increased endogenous regenerative capacity. Moreover, these results provide further rationale for identifying BM cell populations that enhance the repair process with the eventual hope of using this information as a tool to improve the stratification and randomization of patients for cell therapy trials.
Study Limitations
The analyses in this study only show associations between BM cell phenotype and functional outcome and do not identify a causal relationship. Potential confounders in this study were the BM harvest and the transendocardial route of administration. Previous studies have shown that both BM-derived stem cells and resident tissue stem cells actively participate in tissue repair in response to different types of injury 27, [29] [30] [31] . A consideration in cell therapy trials is that the harvest and delivery processes may themselves stimulate this pool of resident stem/progenitor cells, even in placebo-treated subjects, thereby contributing to repair independent of treatment type.
CONCLUSIONS
In this cohort of patients from the FOCUS-CCTRN trial, increased frequencies of B-cell subsets and migratory cells and decreased frequencies of both monocytes/ macrophages and ECFCs in the BM at baseline were associated with improvements in LVEF, LVESV, and VO 2 max, independent of treatment group. This study suggests that both progenitor and immune cell populations in the BM influence the natural history of chronic ischemic cardiomyopathy. When assessing a new therapy, all study groups should have the same baseline characteristics so that the treatment effects can be interpreted accurately. When designing and interpreting the results of cardiovascular disease studies, potential confounding variables, such as age, disease severity, and current comorbidities, must be taken into account. Although we adjusted our findings based on age and CABG, other confounding variables such as BNP could not be addressed. Our study findings suggest that BM composition may be another important factor to consider, as it may affect the endogenous regenerative capacity of the patients.
